Sandoz Stock News

mAbxience and Sandoz have entered into a collaboration agreement combining mAbxience's development and manufacturing expertise with Sandoz's global commercial capabilities for a proposed emicizumab biosimilar candidate. Emicizumab biosimilar expands mAbxience's pipeline into haemophilia A and strengthens its presence in rare diseases.

The approval for its generic version of diabetes drug Ozempic advances its efforts to build a portfolio of GLP-1 medicines.

Sandoz CEO Richard Saynor warned U.S. patients could ultimately bear the cost of threatened tariffs on imported generic drugs. Saynor said manufacturers facing steep tariffs could be forced to raise prices or stop supplying some medicines.

Sandoz aims to more ​than double net sales from ‌2025 to 2035, the Swiss drug maker said on Tuesday at its capital markets day, ​where it outlined its new ​Bio100 biosimilars strategy, pivoting its focus from ⁠generics to biosimilars.

Collaboration may cover up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar assets, with the majority of programs at early development stages Based on the initial arrangements, the total invoiced amount expected to be achieved by Henlius in 2026 is up to US$100.5 million The collaboration further expands the parties' 2025 oncology biosimilars partnership ...

Swiss generic drugmaker Sandoz will pay up to $77 million ​upfront to Shanghai Henlius Biotech for rights to ‌three biosimilar drugs to treat cholesterol, lupus and colorectal cancer, the Chinese drugmaker said on Monday.

Sandoz Group reported higher sales for the second quarter, driven by a strong performance in its biosimilar segment and a return to growth in generics.